Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 10/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29272424 | 1.00 | BRAF (0.42) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL30236908 | 1.00 | BRAF (0.42) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL29272391 | 1.00 | BRAF (0.42) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL29272294 | 1.00 | BRAF (0.42) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL30236644 | 1.00 | BRAF (0.42) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL29272460 | 0.94 | BRAF (0.44) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL30237123 | 0.94 | BRAF (0.44) | BRAFKDRMAPK14MAPK13MAPK12 | |
| SCHEMBL30236297 | 0.91 | RAF1 (0.41) | BRAFRAF1ABL1 | |
| SCHEMBL30236351 | 0.91 | RAF1 (0.41) | BRAFRAF1ABL1 | |
| SCHEMBL29272395 | 0.91 | RAF1 (0.41) | BRAFRAF1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | BRAF 569/4885KDR 2509/4885MAPK14 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.